Dataset from A Phase III, Open-Label, Multicenter, Two Arm, Randomized Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Patients With Previously Untreated Advanced BRAF V600 Wild-Type Melanoma

This is a Phase III, multicenter, open-label, randomized study designed to evaluate the efficacy, safety, and pharmacokinetics of cobimetinib plus atezolizumab compared with pembrolizumab in treatment-naive participants with advanced BRAFV600 wild-type melanoma.

本研究为一项III期多中心开放标签随机对照试验，旨在评估考比替尼（cobimetinib）联合阿替利珠单抗（atezolizumab）对比帕博利珠单抗（pembrolizumab）用于晚期BRAFV600野生型黑色素瘤初治受试者的疗效、安全性与药代动力学特征。